Evaluating the time between cancer diagnosis and treatment is vital. Timely intervention not only improves survival rates, it also reduces patient anxiety and enhances both treatment efficacy and efficiency. Roundtable participants explored ways to ensure equitable access to timely care and how to accelerate the adoption of innovative cancer treatments.
The full recording of the roundtable discussion is now available here. The conclusions, along with examples of system optimisation across Europe, can be found in the roundtable report available here.
The Roundtable was co-chaired by Prof Peter Albers, Professor of Urology, Düsseldorf University & Division Head, German Cancer Research Centre (DKFZ); and Aleksandra Kaczmarek, Public Policy Manager, Digestive Cancers Europe.
16:00 – 16:10 Welcome and introductions
Prof Peter Albers and Aleksandra Kaczmarek introduced the concepts and themes of the roundtable. The introduction also included a presentation from Zoë Parker, Policy Research and EU Projects Assistant, ECO European Cancer Pulse team.
Co-Chaired by Aleksandra Kaczmarek, Public Policy Manager, Digestive Cancers Europe and Jose Luis Gomez Ruiz, Vice President, Public Policy and Advocacy Europe, Middle East and Africa, BD
Speakers and panellists presented and commented upon the role of digitisation in reducing waiting times from a variety of perspectives. Prof Jesus Garcia-Foncilla, President, ECO Foundation, presented the experience of the OncoOptimal project as a case study.
16:55 – 17:40 Means and methods to better coordinate the patient pathway
Co-chaired by Prof Peter Albers, Professor of Urology, Düsseldorf University & Division Head, German Cancer Research Center (DKFZ) and Dr Ilya Gipp, Chief Medical Officer, GE HealthCare
Speakers and panellists presented and commented upon the role of digitisation in reducing waiting times from a variety of perspectives. Prof Jesus Garcia-Foncilla, President, ECO Foundation, presented the experience of the OncoOptimal project as a case study.
17:40 – 18:25 Tackling delay in new treatment access
Co-chaired by Aleksandra Kaczmarek, Public Policy Manager, Digestive Cancers Europe and James Laubner, Director International Government Affairs - Europe, Canada, Mid-East, Africa and Latin America, Amgen
Rebecca Steele, Secretariat, European Alliance for Value in Health
Speakers and panellists presented and commented on the role of early access schemes in providing patients with access to new treatments in accelerated time pathways. Mihai Rotaru, Director Market Access at EFPIA, presented the main results of the Patients W.A.I.T. Indicator Survey series. Marie Phillips, from Tufts University School of Medicine, presented recent research on multi-stakeholder perspectives on managing accelerated patient access to potentially beneficial medicines.